To assess whether 12-month changes in sexual function and related outcomes differed between fractional carbon dioxide laser therapy (CLT) and sham laser therapy (SLT) among breast cancer survivors taking aromatase inhibitors.
Approach:
Design: Exploratory, ad hoc secondary analysis of the single-center, double-blind, sham-controlled LIGHT randomized clinical trial.
Participants and treatment: Eighty-four breast cancer survivors taking aromatase inhibitors, with genitourinary syndrome of menopause and dyspareunia, were randomized equally to five monthly fractional carbon dioxide laser therapy (CLT) or sham laser therapy (SLT) sessions. Participants were sexually active or interested in future sexual activity. Both groups received first-line nonhormonal therapy, including moisturizers and/or lubricants and vibrators.
Outcomes: The primary outcome was the between-group difference in change in Female Sexual Function Index (FSFI) total score from baseline to month 12. Secondary comparisons assessed dyspareunia, sexual activity, body image, quality of life, vaginal health, objective measures of vaginal status, and safety.
Key Findings:
The supplied excerpt describes the study design and outcomes but does not report the 12-month results.
Interpretation:
The context establishes that the analysis compared 12-month outcomes between CLT and SLT, but it does not report whether the groups differed.
Limitations:
The analysis was exploratory and ad hoc.
The study was conducted at a single center.
The supplied excerpt does not report the 12-month results.
Conclusion:
The analysis compared 12-month changes in sexual function and related outcomes between CLT and SLT, but the supplied excerpt does not report the results.
